UK Markets close in 4 hrs 7 mins

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
118.07-4.08 (-3.34%)
At close: 04:00PM EDT
118.31 +0.24 (+0.20%)
Pre-market: 07:16AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close122.15
Open119.90
Bid118.35 x 1000
Ask0.00 x 1100
Day's range115.03 - 120.49
52-week range115.03 - 376.65
Volume4,757,236
Avg. volume4,854,423
Market cap47.871B
Beta (5Y monthly)1.65
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

    EQS Newswire / 12/09/2022 / 23:52 EST/EDTMinistry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214CAMBRIDGE, MA / ACCESSWIRE / September 12, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a p

  • EQS Group

    Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

    EQS Newswire / 08/09/2022 / 23:42 EST/EDTModerna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D DayInterim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefitInterim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance trial shows mRNA-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefitModern

  • EQS Group

    Moderna, Inc.: Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

    DGAP-News: Moderna, Inc. / Key word(s): MiscellaneousModerna, Inc.: Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day 08.09.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D DayInterim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefitInter